Skip to main content

Commercial feasibility of an anti-bacterial treatment

Project description

Finding a solution for AMR

Antimicrobial resistance (AMR) is a major global threat to human and animal health. Medicines that were once effective treatments for disease are becoming less so, leading to a reduced ability to successfully treat infections. The EU-funded ABOLED project is investigating the commercial viability of an alternative approach to this problem. AMR is responsible for an estimated 33 000 deaths per year in the EU. It is also estimated that AMR costs the EU EUR 1.5 billion per year in healthcare costs and productivity losses. Only 25 % of countries have implemented a national policy to tackle AMR. Less than 40 % of countries have put in place infection prevention and control programmes for AMR.

Field of science

  • /medical and health sciences/health sciences/public and environmental health
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance
  • /medical and health sciences/clinical medicine/transplantation
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/multidrug resistance

Call for proposal

ERC-2019-PoC
See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
Address
North Street 66 College Gate
KY16 9AJ St Andrews
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 150 000

Beneficiaries (1)

THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
United Kingdom
EU contribution
€ 150 000
Address
North Street 66 College Gate
KY16 9AJ St Andrews
Activity type
Higher or Secondary Education Establishments